Review of the Therapeutic Uses of Liraglutide

摘要: Abstract Background Glucagon-like peptide (GLP-1) is a neuroendocrine hormone that increases blood glucose and drug target for treatment of type 2 diabetes. Liraglutide, subcutaneous, once-daily GLP-1 agonist, approved the diabetes in United States Europe. It also has been studied weight loss. Objective The purpose this article to review all relevant literature on chemistry, pharmacology, pharmacokinetics, metabolism, clinical trials, safety, interactions, cost, place therapy liraglutide. Methods Literature searches MEDLINE between 1969 September 2010, International Pharmaceutical Abstracts 1970 American Diabetes Association Meeting abstracts (2008–2010), European Study (2008–2010) were performed using liraglutide, Victoza , NN2211 as key terms. Results Thirteen randomized controlled trials identified summarized. Liraglutide shown increase glucose-dependent insulin release by 34% to118% reduce postprandial glucagon levels 20%. Studies showed monotherapy combination with glimepiride, metformin, and/or rosiglitazone, lowers glycosylated hemoglobin (HbA 1c ) 0.84% 1.5%. Transient nausea was reported 7% 40% subjects. Severe hypoglycemia—glucose Conclusion safely effectively reduces HbA patients most recent guidelines recommended agonist along metformin second-tier Although Clinical Endocrinologists/American College Endocrinologists' it first-line 6.5% 7.5% if 7.6% 8.5%, liraglutide should be considered who cannot tolerate agents or an additional agent needed help reach goals.